Welcure Drugs & Pharmaceuticals Ltd
Incorporated in 1992, Welcure Drugs And Pharmaceuticals Ltd used to manufacture pharmaceuticals products[1]
- Market Cap ₹ 93.4 Cr.
- Current Price ₹ 8.30
- High / Low ₹ 15.8 / 4.30
- Stock P/E
- Book Value ₹ 5.05
- Dividend Yield 0.00 %
- ROCE -12.3 %
- ROE -24.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company's working capital requirements have reduced from 74.6 days to 45.4 days
Cons
- Company has low interest coverage ratio.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Castings, Forgings & Fastners Industry: Castings & Forgings
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | |
|---|---|---|---|
| 16.36 | 24.67 | 25.67 | |
| 17.92 | 25.91 | 27.68 | |
| Operating Profit | -1.56 | -1.24 | -2.01 |
| OPM % | -9.54% | -5.03% | -7.83% |
| 0.59 | 1.14 | 1.08 | |
| Interest | 0.36 | 0.24 | 0.53 |
| Depreciation | 0.48 | 0.43 | 0.43 |
| Profit before tax | -1.81 | -0.77 | -1.89 |
| Tax % | 4.42% | 11.69% | 2.12% |
| -1.89 | -0.86 | -1.93 | |
| EPS in Rs | -1.40 | -0.64 | -1.43 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -124% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 80% |
| 3 Years: | 3% |
| 1 Year: | 70% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | |
|---|---|---|---|
| Equity Capital | 12.11 | 12.11 | 12.12 |
| Reserves | -2.49 | -3.36 | -5.29 |
| 3.79 | 3.73 | 2.76 | |
| 4.74 | 7.01 | 7.76 | |
| Total Liabilities | 18.15 | 19.49 | 17.35 |
| 6.70 | 6.41 | 6.02 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.38 | 0.38 | 0.28 |
| 11.07 | 12.70 | 11.05 | |
| Total Assets | 18.15 | 19.49 | 17.35 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | |
|---|---|---|---|
| -1.66 | 0.39 | 1.29 | |
| -1.22 | -0.14 | 0.08 | |
| 2.97 | -0.28 | -1.43 | |
| Net Cash Flow | 0.09 | -0.03 | -0.06 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | |
|---|---|---|---|
| Debtor Days | 112.67 | 119.40 | 123.56 |
| Inventory Days | 75.70 | 28.81 | 12.58 |
| Days Payable | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 188.37 | 148.20 | 136.14 |
| Working Capital Days | 110.21 | 68.35 | 45.36 |
| ROCE % | -4.09% | -12.32% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Apr - Certificate under Regulation 74(5) of SEBI(Depository and participants)Regulations,2018 for the Quarter and year ended 31st March 2025.
-
Closure of Trading Window
27 Mar - Closure of trading window until financial results are declared.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 25 Feb
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
21 Feb - Resignation of Company Secretary and Compliance Officer.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Feb - Newspaper Clipping of Unaudited Financial Results of Quarter ended December, 2024
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Company manufactures and markets pharmaceuticals formulations in the form of tablets, capsules, dry syrups, antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarial, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilizers, sedatives and gastrointestinal.